Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer
Targeted drug delivery systems using nanocarriers offer a versatile platform for breast cancer treatment; however, a robust, CD44-targeted niosomal formulation has not been developed and deeply studied (both in vitro and in vivo) yet. Here, an optimized system of epirubicin (Epi)-loaded niosomal nan...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006422001478 |
| _version_ | 1811235645026205696 |
|---|---|
| author | Amirreza Mansoori-Kermani Sadaf Khalighi Iman Akbarzadeh Fazeleh Ranjbar Niavol Hamidreza Motasadizadeh Athar Mahdieh Vahid Jahed Masoud Abdinezhad Nikoo Rahbariasr Mahshid Hosseini Nima Ahmadkhani Behnam Panahi Yousef Fatahi Masoud Mozafari Alan Prem Kumar Ebrahim Mostafavi |
| author_facet | Amirreza Mansoori-Kermani Sadaf Khalighi Iman Akbarzadeh Fazeleh Ranjbar Niavol Hamidreza Motasadizadeh Athar Mahdieh Vahid Jahed Masoud Abdinezhad Nikoo Rahbariasr Mahshid Hosseini Nima Ahmadkhani Behnam Panahi Yousef Fatahi Masoud Mozafari Alan Prem Kumar Ebrahim Mostafavi |
| author_sort | Amirreza Mansoori-Kermani |
| collection | DOAJ |
| description | Targeted drug delivery systems using nanocarriers offer a versatile platform for breast cancer treatment; however, a robust, CD44-targeted niosomal formulation has not been developed and deeply studied (both in vitro and in vivo) yet. Here, an optimized system of epirubicin (Epi)-loaded niosomal nanoparticles (Nio) coated with hyaluronic acid (HA) has been engineered for targeting breast cancer cells. The nanoformulation was first optimized (based on size, polydispersity index, and entrapment efficiency); then, we characterized the morphology, stability, and release behavior of the nanoparticles. Epirubicin release from the HA-coated system (Epi-Nio-HA) showed a 21% (acidic buffer) and 20% (neutral buffer) reduction in comparison with the non-coated group (Epi-Nio). The cytotoxicity and apoptosis results of 4T1 and SkBr3 cells showed an approximately 2-fold increase in the Epi-Nio-HA system over Epi-Nio and free epirubicin, which confirms the superiority of the engineered nanocarriers. Moreover, real-time PCR data demonstrated the down-regulation of the MMP-2, MMP-9, cyclin D, and cyclin E genes expression while caspase-3 and caspase-9 gene expression were up-regulated. Confocal microscopy and flow cytometry studies uncovered the cellular uptake mechanism of the Epi-Nio-HA system, which was CD44-mediated. Furthermore, in vivo studies indicated Epi-Nio-HA decreased mice breast tumor volume by 28% (compared to epirubicin) without side effects on the liver and kidney. Conclusively, our results indicated that the HA-functionalized niosomes provide a promising nanoplatform for efficient and targeted delivery of epirubicin to potentially treat breast cancer. |
| first_indexed | 2024-04-12T11:55:28Z |
| format | Article |
| id | doaj.art-02cfa869d1c74127ba9aeba18bfe202f |
| institution | Directory Open Access Journal |
| issn | 2590-0064 |
| language | English |
| last_indexed | 2024-04-12T11:55:28Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj.art-02cfa869d1c74127ba9aeba18bfe202f2022-12-22T03:34:01ZengElsevierMaterials Today Bio2590-00642022-12-0116100349Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancerAmirreza Mansoori-Kermani0Sadaf Khalighi1Iman Akbarzadeh2Fazeleh Ranjbar Niavol3Hamidreza Motasadizadeh4Athar Mahdieh5Vahid Jahed6Masoud Abdinezhad7Nikoo Rahbariasr8Mahshid Hosseini9Nima Ahmadkhani10Behnam Panahi11Yousef Fatahi12Masoud Mozafari13Alan Prem Kumar14Ebrahim Mostafavi15Department of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, IranDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, IranDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, IranDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, IranDepartment of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranDepartment of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranRudolfs Cimdins Riga Biomaterials Innovations and Development Centre of RTU, Institute of General Chemical Engineering, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Pulka St. 3/3, Riga, LV, 1007, LatviaSchool of Chemical Engineering, College of Engineering, University of Tehran, Tehran, IranPolymer Research Laboratory, Department of Chemistry, Sharif University of Technology, Tehran, IranDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, IranDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, IranDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, IranDepartment of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranDepartment of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran; Corresponding author. Currently at: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; NUS Center for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore; Corresponding author. Cancer Science Institute of Singapore and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA; Corresponding author. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.Targeted drug delivery systems using nanocarriers offer a versatile platform for breast cancer treatment; however, a robust, CD44-targeted niosomal formulation has not been developed and deeply studied (both in vitro and in vivo) yet. Here, an optimized system of epirubicin (Epi)-loaded niosomal nanoparticles (Nio) coated with hyaluronic acid (HA) has been engineered for targeting breast cancer cells. The nanoformulation was first optimized (based on size, polydispersity index, and entrapment efficiency); then, we characterized the morphology, stability, and release behavior of the nanoparticles. Epirubicin release from the HA-coated system (Epi-Nio-HA) showed a 21% (acidic buffer) and 20% (neutral buffer) reduction in comparison with the non-coated group (Epi-Nio). The cytotoxicity and apoptosis results of 4T1 and SkBr3 cells showed an approximately 2-fold increase in the Epi-Nio-HA system over Epi-Nio and free epirubicin, which confirms the superiority of the engineered nanocarriers. Moreover, real-time PCR data demonstrated the down-regulation of the MMP-2, MMP-9, cyclin D, and cyclin E genes expression while caspase-3 and caspase-9 gene expression were up-regulated. Confocal microscopy and flow cytometry studies uncovered the cellular uptake mechanism of the Epi-Nio-HA system, which was CD44-mediated. Furthermore, in vivo studies indicated Epi-Nio-HA decreased mice breast tumor volume by 28% (compared to epirubicin) without side effects on the liver and kidney. Conclusively, our results indicated that the HA-functionalized niosomes provide a promising nanoplatform for efficient and targeted delivery of epirubicin to potentially treat breast cancer.http://www.sciencedirect.com/science/article/pii/S2590006422001478NanomedicineCD44Active targetingBreast cancerHyaluronic acidControlled drug delivery |
| spellingShingle | Amirreza Mansoori-Kermani Sadaf Khalighi Iman Akbarzadeh Fazeleh Ranjbar Niavol Hamidreza Motasadizadeh Athar Mahdieh Vahid Jahed Masoud Abdinezhad Nikoo Rahbariasr Mahshid Hosseini Nima Ahmadkhani Behnam Panahi Yousef Fatahi Masoud Mozafari Alan Prem Kumar Ebrahim Mostafavi Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer Materials Today Bio Nanomedicine CD44 Active targeting Breast cancer Hyaluronic acid Controlled drug delivery |
| title | Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer |
| title_full | Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer |
| title_fullStr | Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer |
| title_full_unstemmed | Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer |
| title_short | Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer |
| title_sort | engineered hyaluronic acid decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer |
| topic | Nanomedicine CD44 Active targeting Breast cancer Hyaluronic acid Controlled drug delivery |
| url | http://www.sciencedirect.com/science/article/pii/S2590006422001478 |
| work_keys_str_mv | AT amirrezamansoorikermani engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT sadafkhalighi engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT imanakbarzadeh engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT fazelehranjbarniavol engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT hamidrezamotasadizadeh engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT atharmahdieh engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT vahidjahed engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT masoudabdinezhad engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT nikoorahbariasr engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT mahshidhosseini engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT nimaahmadkhani engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT behnampanahi engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT youseffatahi engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT masoudmozafari engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT alanpremkumar engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer AT ebrahimmostafavi engineeredhyaluronicaciddecoratedniosomalnanoparticlesforcontrolledandtargeteddeliveryofepirubicintotreatbreastcancer |